RT期刊文章SR电子T1在活性肺结核患者中升高白介素2受体水平以及抗结核性化学疗法后的变化JF欧洲呼吸杂志JF EUR呼吸JF欧洲呼吸JF欧洲呼吸学会SP 70 OP 70 OP 73 VO 8 IS 1 A1 CHAN，CH，CH，CH，CH，CH188bet官网地址a1 lai，ck a1 leung，jc a1 ho，A1 lai，kn yr 1995 ul //www.qdcxjkg.com/content/8/8/1/70.abstract ab soluble soluble soluble soluble soluble intureble interleukin-2受体（SIL-2R）IST淋巴细胞激活的标记。我们已经进行了一项研究，以检查肺结核（TB）患者的血清SIL-2R水平以及抗TB化疗后的变化。招募了44例肺结核或结核性胸腔积液的患者。抗TB化学疗法开始前和1、2、4和6个月，从患者中收集血清。通过酶免疫测定法测量血清SIL-2R水平。治疗前的平均SIL-2R水平为1,452 +/- 103（SEM）U.ML-1，显着高于健康对照受试者（374 +/- 30 U.ML-1）。1个月时的SIL-2R水平没有显着变化，但是从第二个月开始逐渐减少。在第六个月，平均SIL-2R水平为1080 +/- 81 U.ML-1，在治疗前的平均水平明显低于该水平。 However, despite clinical improvement, the sIL-2R levels at the sixth month were still significantly higher than those of control subjects. We conclude that sIL-2R levels were elevated in patients with pulmonary TB and there was a gradual reduction following anti-TB chemotherapy. However, the sIL-2R levels were still higher than control subjects at completion of treatment, suggesting a delayed resolution of the inflammation in patients with pulmonary TB.